SCM
BCAB icon

Suvretta Capital Management’s BioAtla BCAB Stock Holding History

Suvretta Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,084
Closed -$10.4M – 99
2021
Q3 		$10.4M Buy
+7,084
New +$13.8M 0.18% 67

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Suvretta Capital Management's BCAB Position: Q4 2021 in Review

Suvretta Capital Management sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 7,084 shares — an estimated $10.4M sold.

Suvretta Capital Management first reported a position in BCAB in Q3 2021 and held it in 1 quarter. The position peaked at $10.4M in Q3 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

  • Suvretta Capital Management reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 7,084 BioAtla shares in Q4 2021, an estimated $10.4M.
  • Suvretta Capital Management first reported a position in BioAtla in Q3 2021 and held it in 1 quarter.
  • Suvretta Capital Management's BioAtla position peaked at $10.4M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.